Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct;57(Suppl 1):46-49.
doi: 10.20471/acc.2018.57.s1.06.

Cost-Benefit Analysis of the Introduction of Mp-Mri Guided Biopsies in Croatia

Affiliations

Cost-Benefit Analysis of the Introduction of Mp-Mri Guided Biopsies in Croatia

Ivan Pezelj et al. Acta Clin Croat. 2018 Oct.

Abstract

The objective of this study was to determine differential expression of TFF1, TFF2 and TFF3 genes and proteins in breast tumor subtypes. In addition, we investigated the correlation between TFF genes within tumor subgroups, and TFF genes with clinical and pathologic characteristics of the tumor. Study group included 122 patients with surgically removed breast tumors. Samples were investigated using qRT-PCR and immunohistochemistry. TFF1 and TFF3 genes and proteins were expressed in breast tumors, while the levels of TFF2 gene and protein expression were very low or undetectable. TFF1 was significantly more expressed in benign tumors, while TFF3 was more expressed in malignant tumors. Gene and protein expression of both TFF1 and TFF3 was greater in lymph node-negative tumors, hormone positive tumors, tumors with moderate levels of Ki67 expression, and in grade II tumors. A strong positive correlation was found between TFF1 and TFF3 genes, and the expression of both negatively correlated with Ki67 and the level of tumor histologic differentiation. Our results suggest that TFF1 and TFF3, but not TFF2, may have a role in breast tumor pathogenesis and could be used in the assessment of tumor differentiation and malignancy.

Keywords: Prostate cancer, cost benefit; Prostate mp-MRI.

PubMed Disclaimer

References

    1. White J. (2010). The cost of health care in Western countries. Oxford Medicine Online. doi: https://doi.org/10.1093/med/9780199204854.003.030401. 10.1093/med/9780199204854.003.030401 - DOI
    1. Getzen TE. Getzen Model of Long-Run Medical Cost Trends, 2017 Society of Actuaries (Internet) [cited 2018 Jan 5]. Available from: https://www.soa.org/research-reports/2016/research-hlthcare-trends/.
    1. Nguyen PL, Gu X, Lipsitz SR, Choueiri TK, Choi WW, Lei Y, et al. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. J Clin Oncol. 2011;29(12):1517–24. 10.1200/JCO.2010.31.1217 - DOI - PMC - PubMed
    1. Juday TR. Cost-effectiveness Analysis: Problems and Promise for Evaluating Medical Technology. Health Care Technology Policy I: The Role of Technology in the Cost of Health Care. 1994, pp.462-467. https://doi.org/10.1109/HCTP.1994.721326. 10.1109/HCTP.1994.721326 - DOI
    1. Dennis LK, Resnick MI. Analysis of recent trends in prostate cancer incidence and mortality. Prostate. 2000;42(4):247. 10.1002/(SICI)1097-0045(20000301)42:4<247::AID-PROS1>3.0.CO;2-5 - DOI - PubMed

LinkOut - more resources